Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from TDF/FTC/EFV to ABC/3TC/maraviroc for cerebrospinal fluid antiretroviral activity in HIV with neurocognitive impairment
ISRCTN08592155Phase 4Completed
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of maraviroc, abacavir and lamivudine in human immunodeficiency virus infection (HIV), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Cerebrospinal fluid HIV viral suppression below 5 copies/mL. Started Jan 2011; status: completed.
02
Drugs
maravirocabacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN08592155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN08592155.